DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the CURIS LIFESCIENCES LTD (CURIS) share price today?

CURIS LIFESCIENCES LTD (CURIS) is trading at ₹109 on the NSE, up 3.76% on the day. Source: DocStoX.

What is the PE ratio of CURIS LIFESCIENCES LTD?

CURIS LIFESCIENCES LTD has a price-to-earnings (PE) ratio of 10.6 in the Healthcare sector.

What is the market capitalisation of CURIS LIFESCIENCES LTD?

CURIS LIFESCIENCES LTD has a market capitalisation of approximately ₹81 crore.

CURIS LIFESCIENCES LTD

CURIS·NSE·Healthcare

₹109.00▲ +3.95 (+3.76%)

Healthcare · Pharmaceuticals

High-quality returns — 22% on equity

Day₹107.80

₹109.00

52W₹84

₹14840%

Open

₹107.80

High

₹109.00

Low

₹107.80

Prev Close

₹105.05

Volume

5.0K

VWAP

₹108.52

Snapshot

Key fundamentals

Market Cap

₹81 Cr

P/E Ratio

10.58Cheap

P/B Ratio

1.72

EPS

₹10.30

Book Value

₹58.57

ROE

21.80%Strong

ROCE

34.24%Efficient

Dividend Yield

0.00%

Debt / Equity

0.46Moderate

Face Value

₹10.00

52W High

₹147.90

52W Low

₹83.60

Sector

Healthcare

Industry

Pharmaceuticals

Buy

Narrow moatMedium uncertainty

Fair value estimate

₹153

▲ 40.3%upside

Trading at ₹109 — 40% below our estimate

BearFair valueBull

₹106₹153₹176

/100

Business quality — Solid

Growth 90Profitability 71Efficiency 50Valuation 88

Plain English

Our view

High-quality returns — 22% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 0/9)

Strengths

Low debt relative to equity
Strong returns on equity (22%)
Capital is working hard (ROCE 34%)
Revenue compounding 20% over 3 years

Risks

Fundamental red flags (Piotroski 0/9)

How we got there

Fair value methods

Residual income

38% ROE fading to 13% over ~10 yrs, on ₹59 book

₹166

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹106

Analyst target

No analyst coverage

—

Blended fair value₹153

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (22%)
Capital is working hard (ROCE 34%)
Revenue compounding 20% over 3 years
Profit growing 78% a year
Reasonably priced at 11× earnings
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 0/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

10.6Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

21.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

34.2%Efficient

Above 18% means capital is working hard

Debt/Eq

0.46Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹81 Cr

P/B

1.72

EPS

₹10.30

Div Yield

—

What changed

Recent changes

Foreign investors-1.7% stake last quarter
Domestic institutions-5.1% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 10.6×

Growth

Strong

+20% rev CAGR

Profitability

Excellent

21.8% ROE

Financial health

Comfortable

D/E 0.46

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹5.43L Cr

Trades5

VWAP₹108.52

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+19.9%

—

10Y

—

Profit

+77.9%

—

10Y

—

EPS

-29.7%

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 39.0%

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost
Working capital days have increased from 123 days to 232 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 1.74 pts; domestic institutions reduced 5.06 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

68.0%0.00

Public

25.0%+6.81

FII / FPI

1.2%-1.74

DII

5.8%-5.06

Total shareholders

340+304 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter68.03%

FII1.19%

DII5.80%

Public24.98%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]